B7-H3: A Promising Target for Solid Tumor Immunotherapy
Publication Title: B7-H3 as a Universal Target for Solid Tumor Therapy: Clinical Promise and Biological Complexity
Summary
- Question
- This study investigated B7-H3, a molecule involved in immune system regulation, as a potential therapeutic target for treating solid tumors. The researchers explored its expression in cancer and its role in therapies, such as antibody-drug conjugates (ADCs), bispecific antibodies (BsAbs), and chimeric antigen receptor T-cell (CAR-T) therapies.
- Why it Matters
- Solid tumors, including cancers of the lung, breast, and brain, remain challenging to treat effectively. B7-H3 is a promising target because it is highly expressed in cancer cells but minimally present in normal tissues, making it a safer option for therapies. By targeting B7-H3, researchers aim to improve outcomes for patients with various solid tumors while minimizing harm to healthy cells. This research holds potential to advance cancer treatments, particularly for aggressive and hard-to-treat cancers.
- Methods
- The study reviewed clinical trials and preclinical studies targeting B7-H3 in solid tumors. It focused on therapies such as ADCs, BsAbs, and CAR-T cells. Researchers analyzed B7-H3’s expression in tumors, normal tissues, and the tumor microenvironment, as well as its role in immune regulation and tumor growth.
- Key Findings
- B7-H3 was found to be highly expressed in most solid tumors but rarely in normal tissues, making it an ideal therapeutic target. ADCs targeting B7-H3 demonstrated significant response rates in patients with cancers like lung and nasopharyngeal carcinoma, while early CAR-T therapies showed promising but limited results. The study highlighted B7-H3’s role in promoting tumor growth and immune evasion, though its exact mechanisms remain complex and not fully understood.
- Implications
- Targeting B7-H3 could revolutionize cancer treatment by offering more effective and less toxic therapies. ADCs have shown encouraging early results, and CAR-T therapies hold potential for more durable responses. These findings support continued investment in B7-H3-targeted therapies, which may lead to improved survival and quality of life for cancer patients.
- Next Steps
- Future research should clarify the biological roles of B7-H3 and its interactions with other molecules. The development of therapies that enhance immune infiltration in tumors, especially for cancers like glioblastoma, will also be critical. Further clinical trials are needed to refine B7-H3-targeted therapies and assess their long-term effectiveness.
- Funding Information
- This research was supported by the National Institutes of Health (award P50 CA196530). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Full Citation
Huang B, Chen L. B7-H3 as a Universal Target for Solid Tumor Therapy: Clinical Promise and Biological Complexity. Journal Of Clinical Oncology 2025, 44: 335-337. PMID: 41401407, DOI: 10.1200/jco-25-02487.
This AI-assisted summary has been reviewed and approved by at least one of the study's authors to ensure it accurately reflects the research.
Authors
Baozhu Huang
First AuthorLieping Chen, MD, PhD
Last AuthorUnited Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology)